Clearance of aluminum by hemodialysis

Effect of desferrioxamine

D. S. Milliner, G. Hercz, J. H. Miller

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The chelating agent, desferrioxamine (DFO), has been used to facilitate the removal of iron during dialysis and more recently has been utilized in the treatment of patients with Al-related bone disease and encephalopathy. The DFO-Al complex, or aluminoxamine, with a molecular weight of 584, might be expected to traverse the dialysis membranes, and the administration of DFO should enhance the removal of Al by dialysis. Limited information is available regarding the effect of DFO on the kinetics of Al during dialysis. Therefore, we studied dialyzer clearances of Al both before and after the administration of DFO in hemodialysis patients with Al-related disease. The removal of Al by dialysis is minimal, but it can be enhanced by DFO. The effect of DFO is due to an increase in the ultrafilterable fraction of plasma Al and to an increase in the total plasma Al by mobilization of tissue Al stores. Thus, desferrioxamine is effective in enhancing the removal of Al by dialysis in patients with Al-related osteodystrosphy.

Original languageEnglish (US)
JournalKidney International
Volume28
Issue numberSUPPL. 18
StatePublished - 1986
Externally publishedYes

Fingerprint

Deferoxamine
Aluminum
Renal Dialysis
Dialysis
Bone Diseases
Brain Diseases
Chelating Agents
Iron
Molecular Weight
Membranes

ASJC Scopus subject areas

  • Nephrology

Cite this

Milliner, D. S., Hercz, G., & Miller, J. H. (1986). Clearance of aluminum by hemodialysis: Effect of desferrioxamine. Kidney International, 28(SUPPL. 18).

Clearance of aluminum by hemodialysis : Effect of desferrioxamine. / Milliner, D. S.; Hercz, G.; Miller, J. H.

In: Kidney International, Vol. 28, No. SUPPL. 18, 1986.

Research output: Contribution to journalArticle

Milliner, DS, Hercz, G & Miller, JH 1986, 'Clearance of aluminum by hemodialysis: Effect of desferrioxamine', Kidney International, vol. 28, no. SUPPL. 18.
Milliner DS, Hercz G, Miller JH. Clearance of aluminum by hemodialysis: Effect of desferrioxamine. Kidney International. 1986;28(SUPPL. 18).
Milliner, D. S. ; Hercz, G. ; Miller, J. H. / Clearance of aluminum by hemodialysis : Effect of desferrioxamine. In: Kidney International. 1986 ; Vol. 28, No. SUPPL. 18.
@article{196d0643089a430b973334f240b48863,
title = "Clearance of aluminum by hemodialysis: Effect of desferrioxamine",
abstract = "The chelating agent, desferrioxamine (DFO), has been used to facilitate the removal of iron during dialysis and more recently has been utilized in the treatment of patients with Al-related bone disease and encephalopathy. The DFO-Al complex, or aluminoxamine, with a molecular weight of 584, might be expected to traverse the dialysis membranes, and the administration of DFO should enhance the removal of Al by dialysis. Limited information is available regarding the effect of DFO on the kinetics of Al during dialysis. Therefore, we studied dialyzer clearances of Al both before and after the administration of DFO in hemodialysis patients with Al-related disease. The removal of Al by dialysis is minimal, but it can be enhanced by DFO. The effect of DFO is due to an increase in the ultrafilterable fraction of plasma Al and to an increase in the total plasma Al by mobilization of tissue Al stores. Thus, desferrioxamine is effective in enhancing the removal of Al by dialysis in patients with Al-related osteodystrosphy.",
author = "Milliner, {D. S.} and G. Hercz and Miller, {J. H.}",
year = "1986",
language = "English (US)",
volume = "28",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "SUPPL. 18",

}

TY - JOUR

T1 - Clearance of aluminum by hemodialysis

T2 - Effect of desferrioxamine

AU - Milliner, D. S.

AU - Hercz, G.

AU - Miller, J. H.

PY - 1986

Y1 - 1986

N2 - The chelating agent, desferrioxamine (DFO), has been used to facilitate the removal of iron during dialysis and more recently has been utilized in the treatment of patients with Al-related bone disease and encephalopathy. The DFO-Al complex, or aluminoxamine, with a molecular weight of 584, might be expected to traverse the dialysis membranes, and the administration of DFO should enhance the removal of Al by dialysis. Limited information is available regarding the effect of DFO on the kinetics of Al during dialysis. Therefore, we studied dialyzer clearances of Al both before and after the administration of DFO in hemodialysis patients with Al-related disease. The removal of Al by dialysis is minimal, but it can be enhanced by DFO. The effect of DFO is due to an increase in the ultrafilterable fraction of plasma Al and to an increase in the total plasma Al by mobilization of tissue Al stores. Thus, desferrioxamine is effective in enhancing the removal of Al by dialysis in patients with Al-related osteodystrosphy.

AB - The chelating agent, desferrioxamine (DFO), has been used to facilitate the removal of iron during dialysis and more recently has been utilized in the treatment of patients with Al-related bone disease and encephalopathy. The DFO-Al complex, or aluminoxamine, with a molecular weight of 584, might be expected to traverse the dialysis membranes, and the administration of DFO should enhance the removal of Al by dialysis. Limited information is available regarding the effect of DFO on the kinetics of Al during dialysis. Therefore, we studied dialyzer clearances of Al both before and after the administration of DFO in hemodialysis patients with Al-related disease. The removal of Al by dialysis is minimal, but it can be enhanced by DFO. The effect of DFO is due to an increase in the ultrafilterable fraction of plasma Al and to an increase in the total plasma Al by mobilization of tissue Al stores. Thus, desferrioxamine is effective in enhancing the removal of Al by dialysis in patients with Al-related osteodystrosphy.

UR - http://www.scopus.com/inward/record.url?scp=0010519669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0010519669&partnerID=8YFLogxK

M3 - Article

VL - 28

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - SUPPL. 18

ER -